-
Article
Author Correction: An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
-
Article
Combinatorial strategies to target RAS-driven cancers
Although RAS was formerly considered undruggable, various agents that inhibit RAS or specific RAS oncoproteins have now been developed. Indeed, the importance of directly targeting RAS has recently been illust...
-
Article
Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer
Pancreatic ductal adenocarcinoma is an aggressive cancer with limited treatment options1. Approximately 10% of cases exhibit familial predisposition, but causative genes are not known in most families2. We perfor...
-
Article
Loss of negative regulators amplifies RAS signaling
A new study identifies SPRY4 as a tumor suppressor in acute myeloid leukemia and shows that loss of SPRY4 acts as an alternative mechanism to drive RAS signaling. In addition, a paradigm of cooperativity in which...
-
Article
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
SUZ12, a component of the PRC2 complex, can also function as a tumour suppressor in certain tumours of the nervous system and melanomas.
-
Article
Open AccessNeurofibromatosis 2011: a report of the Children’s Tumor Foundation Annual Meeting
The 2011 annual meeting of the Children’s Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of n...
-
Chapter
Advances in NF1 Animal Models and Lessons Learned
Over the past two decades, since the identification of the NF1 tumor suppressor gene, there has been an explosion in our understanding of the molecular mechanisms underlying the initiation and progression of NF1-...
-
Article
Inhibitors that activate
Inhibitors of RAF enzymes can suppress or activate the same signalling pathway. The details of how this happens provide a cautionary note for those targeting the pathway for anticancer drug discovery.
-
Article
An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
Metastasis is a fatal complication of prostate cancer, but its mechanisms remain largely unknown. In this report, the authors identify a signaling pathway commonly deregulated in human prostate cancer and desc...
